Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
BMRN
BMRN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BMRN News
CNBC Launches Advocacy Platform for Rare Diseases
Mar 20 2026
CNBC
BioMarin Discontinues Voxzogo Trials Amid Safety Concerns
Mar 16 2026
seekingalpha
VOXZOGO Treatment Shows Significant Improvements in Children's Skeletal Growth
Mar 12 2026
PRnewswire
VOXZOGO Shows Significant Efficacy in Children
Mar 12 2026
Newsfilter
BridgeBio's Promising Biotech Pipeline Highlighted by William Blair
Mar 10 2026
Benzinga
BioMarin Pharmaceutical Outlines Strategic Refresh and Market Outlook
Mar 07 2026
Yahoo Finance
FDA Grants Approvals for Multiple New Therapies
Mar 06 2026
NASDAQ.COM
UniQure's Gene Therapy Faces FDA Challenges
Mar 05 2026
CNBC
FDA Faces Criticism Amid Innovation Challenges
Mar 03 2026
CNBC
BioMarin's Drug Approved by FDA for PKU Treatment
Mar 02 2026
Benzinga
BioMarin Receives FDA Approval for PALYNZIQ in Pediatric Patients
Feb 28 2026
NASDAQ.COM
FDA Approves PALYNZIQ for Pediatric PKU Treatment in Adolescents
Feb 28 2026
PRnewswire
FDA Approves PALYNZIQ for Adolescent PKU Treatment
Feb 28 2026
Newsfilter
FDA Grants Approval for Biomarin's Palynziq® (Pegvaliase-PQPZ) for Adolescents Aged 12 and Up with Phenylketonuria (PKU)
Feb 28 2026
moomoo
BioMarin Reports Mixed Q4 Results with Earnings Miss
Feb 25 2026
Benzinga
BioMarin Reports Strong 2025 Earnings Growth
Feb 24 2026
seekingalpha
Show More News
